Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Journal of Clinical Investigation

Volumn 111, Issue 9, 2003, Pages 1287-1295

  Bergers, Gabriele ^a,b   Song, Steven ^a,b   Meyer Morse, Nicole ^c   Bergsland, Emily ^b   Hanahan, Douglas ^b,c  

^a Brain Tumor Research Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; IMATINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; SEMAXANIB; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; FEMALE; INHIBITION KINETICS; LUNG HEMORRHAGE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET CELL CARCINOMA; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VASCULARIZATION; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD VESSELS; CARCINOMA, ISLET CELL; ENDOTHELIUM, VASCULAR; FEMALE; INDOLES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN-TYROSINE KINASES; PYRROLES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 0038476608     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200317929     Document Type: Article

References (43)

1. Folkman, J. 2000. Tumor angiogenesis. In Cancer medicine. R.C. Bast, Jr., et al., editors. D.C. Decker Inc. Hamilton, Ontario, Canada. 2546 pp.
2. Kerbel, R., and Folkman, J. 2002. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer. 2:727-739.
3. Bergers, G., Javaherian, K., Lo, K.M., Folkman, J., and Hanahan, D. 1999. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284:808-812.
4. Hanahan, D., Christofori, G., Naik, P., and Arbeit, J. 1996. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur. J. Cancer. 32A:2386-2393.
5. Folkman, J., Watson, K., Ingber, D., and Hanahan, D. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 339:58-61.
6. Hanahan, D., and Folkman, J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353-364.
7. Huss, W., Hanrahan, C., Barrios, R., Simons, J., and Greenberg, N. 2001. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res. 61:2736-2743.
8. Hanahan, D. 1985. Heritable formation of pancreatic β-cell tumors in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature. 315:115-122.
9. Bergers, G., Hanahan, D., and Coussens, L.M. 1998. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Int. J. Dev. Biol. 42:995-1002.
10. Lopez, T., and Hanahan, D. 2002. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 4:339-353.
11. Fong, T.A., et al. 1999. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Fk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:99-106.
12. Bergers, G., et al. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2:737-744.
13. Bergers, G., and Hanahan, D. 2003. Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. Cold Spring Harb. Symp. Quant. Biol. 67:293-300.
14. Inoue, M., et al. 2002. VEGF-A has a critical non-redundant role in angiogenic switching and pancreatic β-cell carcinogenesis. Cancer Cell. 1:193-202.
15. Browder, T., et al. 2000. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:1878-1886.
16. Klement, G., et al. 2000. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor without overt toxicity. J. Clin. Invest. 105:R15-R24.
17. Dash, A.B., et al. 2002. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc. Natl. Acad. Sci. U. S. A. 99:7622-7627.
18. Parangi, S., Dietrich, W., Christofori, G., Lander, E.S., and Hanahan, D. 1995. Tumor suppressor loci on mouse chromosome 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma. Cancer Res. 55:6071-6076.
19. Vajkoczy, P., et al. 1999. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia. 1:31-41.
20. Laird, A.D., et al. 2000. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 60:4152-4160.
21. Laird, A.D., et al. 2002. SU6668 inhibits Flk-1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J. 16:681-690
22. Fabbro, D., and Manley, P.W. 2001. Su-6668. SUGEN. Curr. Opin. Investig. Drugs. 2:1142-1148.
23. Solorzano, C.C., et al. 2001. In vivo intracellular signaling as a marker of antiangiogenic activity. Cancer Res. 61:7048-7051.
24. Reinmuth, N., et al, 2001. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J. 15:1239-1241.
25. Vajkoczy, P., et al. 2000. Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications. Oncologist. 5(Suppl. 1):16-19.
26. Nehls, V., and Drenckhahn, D. 1993. The versatility ofmicrovascular pericytes: from mesenchyme to smooth muscle? Histochemistry. 99:1-12.
27. Hirschi, K.K., and D'Amore, P.A. 1996. Pericytes in the microvasculature. Cardiovasc. Res. 32:687-698.
28. Morikawa, S., et al. 2002. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160:985-1000.
29. Shaheen, R.M., et al. 2001. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res. 61:1464-1468.
30. Lindahl, P., Johansson, B., Leveen, P., and Betsholtz, C. 1997. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 277:242-245.
31. Hellstrom, M., Kaln, M., Lindahl, P., Abramsson, A., and Betsholtz, C. 1999. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development. 126:3047-3055.
32. Hellstrom, M., et al. 2001. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell Biol. 153:543-553.
33. Compagni, A., Wilgenbus, P., Impagnatelio, M.A., Cotten, M., and Christofori, G. 2000. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 60:7163-7169.
34. Buchdunger, E., Matter, A., and Druker, B.J. 2001. Bcr-Abl inhibition as a modality of CML therapeutics. Biochim. Biophys. Acta. 1551:M11-M18.
35. Druker, B.J. 2002. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol. Med. 8(Suppl.):S14-S18.
36. Hirschi, K.K., and D'Amore, P.A. 1997. Control of angiogenesis by the pericyte: molecular mechanisms and significance. EXS. 79:419-428.
37. Benjamin, L., Hemo, I., and Keshet, E. 1998. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed enclothelial network and is regulated by PDGF-B and VEGF. Development. 125:1591-1598.
38. Pietras, K., et al. 2001. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61:2929-2934.
39. Sternlicht, M., and Bergers, G. 2000. Matrix metalloproteinases as emerging targets in cancer: status and prospects. ETT. 4:609-633.
40. Coussens, L.M., Fingleton, B., and Matrisian, M. 2002. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 295:2387-2392.
41. Ferrata, N. 2002. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29:10-14.
42. Laird, A.D., and Cherrington, J.M. 2003. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin. Investig. Drugs. 12:51-64.
43. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell. 100:57-70.